Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Indian Spice Ingredient Kills Cancer Cells

By BiotechDaily International staff writers
Posted on 10 Nov 2009
A new study has revealed that curcumin, a compound found in the spice Turmeric, kills esophageal cancer cells in the laboratory via an unforeseen cell-death mechanism.

Researchers at University College Cork (UCC, Ireland) found that curcumin treatment of an esophageal cancer cell line reduced the viability of all cells within 24 hours of treatment. Since the common path of cell death is apoptosis--a cell suicide path triggered by proteins called caspases--the researchers added a molecule that stops the caspases triggering apoptosis, and found that it made no difference to the number of cells that died. The curcumin seems to induce cell death by a mechanism that was not reliant on apoptosis induction, and in fact, the cells began to digest themselves. The study was published in the October 28, 2009, issue of the British Journal of Cancer.

"The incidence of esophageal cancer has gone up by more than a half since the 70's, particularly in the Western world, and this is thought to be linked to rising rates of obesity, alcohol intake and reflux disease, so finding ways to both treat and prevent this disease is extremely important,” said study coauthor Professor Gerald O'Sullivan, M.D., Ph.D., who heads the Cork Cancer Research Center (CCRC) at UCC. "The development of natural compounds as chemo-preventative agents is also a very promising area of research.”

Curcumin is the principal curcuminoid of the ginger family (Zingiberaceae); the other two curcuminoids are desmethoxycurcumin and bis-desmethoxycurcumin. The curcuminoids are polyphenols and thus responsible for the yellow color of turmeric, which has been used historically as a component of Indian Ayurvedic medicine since 1900 BCE to treat a wide variety of ailments. A recent study on curcumin effects on cancer stated that curcumin modulates growth of tumor cells through regulation of multiple cell signaling pathways, including the cell proliferation pathway, cell survival pathway, caspase activation pathway, tumor suppressor pathway, death receptor pathway, mitochondrial pathways, and the protein kinase pathway.

Related Links:

University College Cork



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.